Contact Us
Drug Search Results
More Filters [+]

BIIB021

Alternative Names: biib021, cnf2024
Latest Update: 2024-03-04
Latest Update Note: PubMed Publication

Product Description

 BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19372565/)

Mechanisms of Action: HSP90 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BIIB021

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Gastrointestinal Stromal Tumors|Breast Cancer

Phase 1: Lymphocytic Chronic B-Cell Leukemia|Oncology Solid Tumor Unspecified|Chronic Lymphoid Leukemia|Lymphoma|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2009-014796-51

P2

Completed

Breast Cancer

2011-10-31

120BC201

P2

Completed

Breast Cancer

2011-10-01

120BC101

P1

Completed

Breast Cancer

2011-04-01

120ST104

P1

Completed

Oncology Solid Tumor Unspecified

2010-08-01

Recent News Events

Date

Type

Title

03/04/2024

PubMed

 A novel PET probe to selectively image heat shock protein 90α/β isoforms in the brain.

01/19/2024

PubMed

 Molecular mechanism of anticancer effect of heat shock protein 90 inhibitor BIIB021 in human bladder cancer cell line.

08/01/2023

PubMed

 BIIB021, an orally available and small-molecule inhibitor of HSP90, activates intrinsic apoptotic pathway in human cervical adenocarcinoma cell line (HeLa).

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions